UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

 

FORM 8-K

_____________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 21, 2014

 

TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware (State or Other Jurisdiction of Incorporation)

001-32639 (Commission File Number)

36-3898269 (IRS Employer Identification No.)

 

3 Columbus Circle, 15^th Floor

New York, New York 10019

(Address of Principal Executive Offices)

 

(212) 554-4484

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act.

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

¨

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

  

  

 

Item 2.02. Results of Operations and Financial Condition.

 

On July 21, 2014, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the second quarter ended June 30, 2014. TG also announced that on Tuesday, July 22, 2014 at 8:30am EST, TG would host an investor conference call during which the Company would provide a brief financial overview of its second quarter financial results and discuss the preliminary clinical data released on July 21, 2014 on the Company’s proprietary combination of TG-1101 and TGR-1202. A copy of such press release is being furnished as Exhibit 99.1.

 

Item 9.01        Financial Statements And Exhibits.

 

(d)	Exhibits.
99.1	Press release issued by TG Therapeutics, Inc., dated July 21, 2014.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	TG Therapeutics, Inc.
	(Registrant)

 

Date: July 21, 2014

 

	By:	/s/ Sean A. Power
		Sean A. Power
		Chief Financial Officer

 

 

INDEX TO EXHIBITS

 

Exhibit
Number		Description
99.1		Press release issued by TG Therapeutics, Inc., dated July 21, 2014.